Pfizer Inc. (PFE)
After hours:
| Previous Close | 53.37 |
| Open | 53.77 |
| Bid | 54.51 x 1400 |
| Ask | 54.60 x 2200 |
| Day's Range | 53.10 - 54.67 |
| 52 Week Range | 33.36 - 61.71 |
| Volume | |
| Avg. Volume | 45,653,990 |
| Market Cap | 304.947B |
| Beta (5Y Monthly) | 0.62 |
| PE Ratio (TTM) | 15.52 |
| EPS (TTM) | 3.50 |
| Earnings Date | Feb. 08, 2022 |
| Forward Dividend & Yield | 1.60 (2.93%) |
| Ex-Dividend Date | Jan. 27, 2022 |
| 1y Target Est | N/A |
- Editor's PickYahoo Finance Video
Omicron: Military medical team helping New Jersey amid coronavirus wave
University Hospital CEO and former NJDOH Commissioner Dr. Shereef Elnahal joins Yahoo Finance Live to discuss how 25 military personnel are helping with staff shortages.
- Editor's PickYahoo Finance Video
Coronavirus: What to know about ‘stealth’ COVID variant hitting Europe, Asia
BA.2 Omicron subvariant is appearing in Europe and Asia. Yahoo Finance's Anjalee Khemlani explains everything we know about this coronavirus strain so far.
- Reuters
COVID SCIENCE-Easier to produce COVID vaccine shows promise in trials; nasal spray vaccine booster works in mice
A COVID-19 vaccine that can be produced locally in low- and middle-income countries is yielding promising results in early clinical trials, researchers say. The NDV-HXP-S vaccine, developed at Icahn School of Medicine at Mount Sinai in New York City, uses an engineered version of the harmless Newcastle disease virus studded with coronavirus spike proteins to teach the immune system to recognize and attack the virus that causes COVID. Using blood samples from trial participants, researchers found that NDV-HXP-S induces proportionally more antibodies that can neutralize the virus and fewer non-neutralizing antibodies than the current mRNA vaccines from Moderna or Pfizer/BioNTech, they reported on Friday on medRxiv https://www.medrxiv.org/content/10.1101/2022.01.25.22269808v1 ahead of peer review.
